Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions

被引:6
作者
Klemencic Kozul, Tara [1 ]
Yudina, Anna [2 ]
Donovan, Carley [1 ]
Pinto, Ashwin [1 ]
Osman, Chinar [1 ]
机构
[1] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
[2] Terumo Blood & Cell Technol Europe, Zaventem, Belgium
关键词
Plasma exchange (PLEX); Intravenous immunoglobulin (IVIg); Cost-minimisation; Autoimmune neurological disorders; Cost effectiveness; INTRAVENOUS IMMUNOGLOBULIN; ADVERSE EVENTS; PLASMAPHERESIS; COMPLICATIONS; SAFETY; GUIDELINES; APHERESIS; THERAPY; UPDATE; TRIAL;
D O I
10.1186/s12913-022-08210-z
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Plasma exchange (PLEX) is an effective treatment for antibody-mediated neurological disorders and has been shown to be equally efficacious to intravenous immunoglobulin (IVIg) with comparable adverse event profiles. IVIg has traditionally been the preferred treatment option due to its ease of use. However, advancing technology has allowed PLEX to be performed with a centrifugal system via peripheral access as opposed to central access via a membrane filter. Methods We prospectively collected data from a cohort of patients who underwent PLEX at the Wessex Neurological Centre, UK, to perform a cost-minimisation analysis comparing PLEX to IVIg, the standard of care, between May 2019 and May 2020. Data obtained included indication, admission type (inpatient, daycase or intensive care), access (peripheral or central), number of PLEX cycles, exchange volume, patient weight, complications and clinical outcomes. The cost of PLEX delivered in an outpatient setting for an average 80kg person was calculated and compared to the equivalent cost of delivering IVIg by means of a cost-minimization model. Results The provision of PLEX was roughly half as costly when compared to what it would have been for IVIg (886 pound per exchange vs 1778 pound per infusion or 4432 pound per cycle of 5 exchanges vs 8890 pound per cycle of 5 infusions). Our cohort included a total of 44 patients who received a total of 357 PLEX exchanges during the 12-month period (the majority of which were in a daycase setting). We calculated an annual cost saving for PLEX over IVIg of 318,589 pound. The robustness of this result was confirmed by a one-way deterministic sensitivity analysis, showing the cost-effectiveness of PLEX. Conclusion Our findings demonstrate that PLEX is more cost-effective than IVIg in this setting. Our study supports the economic case for development of plasma exchange centres in regional neurology units, a case made all the more relevant in the context of constrained supplies of IVIg.
引用
收藏
页数:10
相关论文
共 50 条
[21]   Safety and tolerability of therapeutic plasma exchange in autoimmune neurological diseases - a retrospective single-centre analysis [J].
Gala-Bladzinska, Agnieszka ;
Mazur, Katarzyna ;
Debiec, Adam ;
Gargasz, Krzysztof ;
Bartosik-Psujek, Halina .
NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2020, 54 (04) :344-349
[22]   Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis [J].
Le Masson, Gwendal ;
Sole, Guilhem ;
Desnuelle, Claude ;
Delmont, Emilien ;
Gauthier-Darnis, Marc ;
Puget, Sophie ;
Durand-Zaleski, Isabelle .
BRAIN AND BEHAVIOR, 2018, 8 (02)
[23]   Therapeutic Plasma Exchange Versus FcRn Inhibition in Autoimmune Disease [J].
Mina-Osorio, Paola ;
Tran, Minh -Ha ;
Habib, Ali A. .
TRANSFUSION MEDICINE REVIEWS, 2024, 38 (01)
[24]   Therapeutic plasma exchange in patients with neurological diseases: Multicenter retrospective analysis [J].
Kaya, Emin ;
Keklik, Muzaffer ;
Sencan, Mehmet ;
Yilmaz, Mehmet ;
Keskin, Ali ;
Kiki, Ilhami ;
Erkurt, Mehmet Ali ;
Sivgin, Serdar ;
Korkmaz, Serdal ;
Okan, Vahap ;
Dogu, Mehmet Hilmi ;
Unal, Ali ;
Cetin, Mustafa ;
Altuntas, Fevzi ;
Ilhan, Osman .
TRANSFUSION AND APHERESIS SCIENCE, 2013, 48 (03) :349-352
[25]   Therapeutic Plasma Exchange as a Therapeutic Modality for the Treatment of IVIG Complications [J].
Welsh, Kerry J. ;
Bai, Yu .
JOURNAL OF CLINICAL APHERESIS, 2015, 30 (06) :371-374
[26]   Cost-Minimisation Analysis of Oral Anticoagulant Therapy Monitoring Methods: The Case for Prothrombin Time Self-Monitoring [J].
Geitona, Mary ;
Hollandezos, Mark ;
Souliotis, Kyriakos ;
Athanasakis, Kostas ;
Kyriopoulos, John .
HELLENIC JOURNAL OF CARDIOLOGY, 2008, 49 (06) :388-396
[27]   Cost-minimisation Analysis from a Non-inferiority Trial of Ready-Made versus Custom-Made Spectacles for School Children in India [J].
Minakaran, Neda ;
Morjaria, Priya ;
Frick, Kevin D. ;
Gilbert, Clare .
OPHTHALMIC EPIDEMIOLOGY, 2021, 28 (05) :383-391
[28]   Cost-minimisation model of magnetic resonance-guided focussed ultrasound therapy compared to unilateral deep brain stimulation for essential tremor treatment in Japan [J].
Igarashi, Ataru ;
Tanaka, Midori ;
Abe, Keiichi ;
Richard, Lance ;
Peirce, Vivian ;
Yamada, Kazumichi .
PLOS ONE, 2019, 14 (07)
[29]   Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy [J].
Novello, S ;
Kielhorn, A ;
Stynes, G ;
Selvaggi, G ;
De Marinis, F ;
Maestri, A ;
Foggi, P ;
Tilden, D ;
Tonato, M ;
Crinò, L ;
Rinaldi, M ;
Migliorino, AM ;
Scagliotti, GV .
LUNG CANCER, 2005, 48 (03) :379-387
[30]   Cost minimisation using clinic-based treatment for common hand conditions - a prospective economic analysis [J].
Webb, J. A. ;
Stothard, J. .
ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2009, 91 (02) :135-139